The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ISIS CRP Rx and its effects on CRP and other pharmacodynamic measures, versus placebo, in subjects with active rheumatoid arthritis.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01414101?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
